Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Orforglipron for sleep apnea: ATTAIN-OSA
ATTAIN-OSA is testing an oral GLP-1 pill against sleep apnea. Here is what the 712-participant protocol measures and how it compares to SURMOUNT-OSA.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
Masters athletes: supplement review 2026
A 2026 review in Current Sports Medicine Reports assessed protein, creatine, BPC-157, and TB-500 in adults over 55. Evidence is uneven.
Tesamorelin: what a cognition trial found
A 2026 pilot of low-dose tesamorelin found no significant changes on cognitive tests. Machine learning flagged shifts in two brain regions linked to attention.
Tirzepatide vs semaglutide: real-world data
A 511-patient real-world study in Mayo Clinic Proceedings found tirzepatide produced 16.6% vs 13.4% mean weight loss for semaglutide over 12 months.
Bofanglutide vs semaglutide in Chinese T2D
Ann Intern Med Phase 2b: bofanglutide 18 mg biweekly cut HbA1c by 2.28 points versus 1.60 for semaglutide 1 mg weekly in Chinese patients with type 2 diabetes.
BPC-157 and TB-500 for injury recovery
BPC-157 and TB-500 show tissue-repair effects in animal models, but no human randomised controlled trial exists for either peptide in musculoskeletal injury.
CagriSema pen usability: the study results
A 150-person study tested whether adults with overweight or diabetes could use the CagriSema dual-chamber autoinjector correctly after 3 minutes of training.
CircRNA with full nucleoside modification
A Fudan University circRNA platform combines nucleoside modification with rolling-circle translation, matching semaglutide in obese mice.
GLP-1 drugs in Medicaid: the coverage gap
Most US Medicaid programs restrict or exclude GLP-1 obesity drugs. Here is what the research says about who gets access and why coverage varies by state.
Health Canada vs FDA: approval paths
A 2026 JGIM study compares how Health Canada and the FDA use expedited pathways, with implications for Canadian patients waiting on GLP-1 approvals.